RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS

• US 20110076318A1
• Filed: 12/07/2010
• Published: 03/31/2011
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Huang, Glenn Tony, Shiah, JaneGuo, Sarrazin, Christian, Chang-Lin, Joan-En, Boix, Michele, Nivaggioli, Thierry, Olejnik, Orest, Hughes, Patrick M.
• Application Number:
  US12/962,427
• Publication Number:
  US 20110076318A1
• Time in Patent Office: Days
• US Class Current: 424/425
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.

Claims

1. A biodegradable intraocular drug delivery system comprising:

a retinoid component and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the retinoid component from the drug delivery system for at least about one week after the drug delivery system is placed in an eye.

2. The system of claim 1, wherein the retinoid component comprises at least one of a retinoid and a retinoid precursor.

3. The system of claim 1, wherein the retinoid component includes an retinoic acid receptor agonist.

4. The system of claim 1, wherein the retinoid component includes a tazarotene, salts thereof, and mixtures thereof.

5. The system of claim 1, wherein the retinoid component includes a tazarotenic acid.

6. The system of claim 1, further comprising an additional ophthalmically acceptable therapeutic agent.

7. The system of claim 1, wherein the retinoid component is dispersed within the biodegradable polymer matrix.

8. The system of claim 1, wherein the matrix comprises at least one polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), derivatives thereof, and mixtures thereof.

9. The system of claim 1, wherein the system is sterile.

10. The system of claim 1, wherein the matrix comprises a poly (lactide-co-glycolide).

11. The system of claim 1, wherein the matrix comprises a poly(D,L-lactide-co-glycolide).

12. The system of claim 1, wherein the matrix releases drug at a rate effective to sustain release of an amount of the retinoid component from the drug delivery system for more than one month from the time the system is placed in the vitreous of the eye.

13. The system of claim 1, wherein the retinoid component is a tazarotene or tazarotenic acid, and the matrix releases drug at a rate effective to sustain release of a therapeutically effective amount of the tazarotene or tazarotenic acid for a time from about two months to about six months.

14. The system of claim 1, wherein the implant is structured to be placed in the vitreous of the eye.

15. The system of claim 1, wherein the retinoid is tazarotene or tazarotenic acid provided in an amount from about 40% by weight to about 70% by weight of the implant, and the biodegradable polymer matrix comprises a poly (lactide-co-glycolide) in an amount from about 30% by weight to about 60% by weight of the drug delivery system.

16. The system of claim 1 formed as a rod, a wafer, a plug, or a particle.

17. The system of claim 1 which is formed by an extrusion process.

18. A method of making a biodegradable intraocular drug delivery system, comprising the step of:

extruding a mixture of a retinoid and a biodegradable polymer component to form a biodegradable material that degrades at a rate effective to sustain release of an amount of the retinoid from the drug delivery system for at least about one week after the drug delivery system is placed in an eye.

19. The method of claim 18, wherein mixture consists essentially of an RAR agonist and a biodegradable polymer.

20. The method of claim 18, further comprising a step of mixing the retinoid with the polymer component before the extrusion step.

21. The method of claim 18, wherein the retinoid component and the polymer component are in a powder form.

22. The method of claim 18, wherein the polymer component comprises a polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), and combinations thereof.

23. The method of claim 18, wherein the polymer component is substantially free of polyvinyl alcohol.

24. A method of improving or maintaining vision in an eye of a patient, comprising the step of placing a biodegradable intraocular drug delivery system in an eye of the patient, the drug delivery system comprising a retinoid component and a biodegradable polymer matrix, wherein the drug delivery system degrades at a rate effective to sustain release of an amount of the retinoid component from the drug delivery system effective to improve or maintain vision in the eye of the patient.

25. The method of claim 24, wherein the method is effective to treat a retinal ocular condition.

26. The method of claim 24, wherein the ocular condition includes proliferative vitreoretinopathy.

27. The method of claim 24, wherein the drug delivery system is placed in the posterior of the eye.

28. The method of claim 24, wherein the drug delivery system is placed in the eye with a trocar.

29. The method of claim 24, wherein the drug delivery system is placed in the eye with a syringe.

30. The method of claim 24, further comprising a step of administering a therapeutic agent in addition to the retinoid component to the patient.

31. The method of claim 24, wherein the retinoid component includes at least one of tazarotene, tazarotenic acid, salts thereof, and mixtures thereof.